Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | FDPS | P14324 | 8/20 | 0.41 |
| ▸ | GGPS1 | O95749 | 5/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.39 |
| ▸ | GMNN | O75496 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CETP | P11597 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | UBE2N | P61088 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28434703 | 1.00 | LMNA (0.41) | LMNAFDPSGGPS1CYP2D6SPHK1 | |
| SCHEMBL18863212 | 1.00 | LMNA (0.41) | LMNAFDPSGGPS1CYP2D6SPHK1 | |
| SCHEMBL1890334 | 1.00 | LMNA (0.41) | LMNAFDPSGGPS1CYP2D6SPHK1 | |
| SCHEMBL5820256 | 1.00 | LMNA (0.41) | LMNAFDPSGGPS1CYP2D6SPHK1 | |
| SCHEMBL25815 | 1.00 | LMNA (0.41) | LMNAFDPSGGPS1CYP2D6SPHK1 | |
| SCHEMBL142854 | 1.00 | LMNA (0.41) | LMNAFDPSGGPS1CYP2D6SPHK1 | |
| SCHEMBL2226505 | 1.00 | LMNA (0.41) | LMNAFDPSGGPS1CYP2D6SPHK1 | |
| SCHEMBL5963212 | 1.00 | LMNA (0.41) | LMNAFDPSGGPS1CYP2D6SPHK1 | |
| SCHEMBL136611 | 1.00 | LMNA (0.41) | LMNAFDPSGGPS1CYP2D6SPHK1 | |
| SCHEMBL29064953 | 1.00 | LMNA (0.41) | LMNAFDPSGGPS1CYP2D6SPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 180 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117384055-B | Ionizable lipids for delivery of therapeutic agents and uses thereof | 仁景(苏州)生物科技有限公司 | 2024-11-19 | — | — | CN | claimed |
| WO-2024222243-A1 | IONIZABLE LIPID FOR DELIVERY OF THERAPEUTIC AGENT AND USE THEREOF | 仁景(苏州)生物科技有限公司 | 2024-10-31 | — | — | WO | claimed |
| CN-118813629-A | MRNA for expressing aquaporin AQP3 and application thereof | 北京键凯科技股份有限公司 | 2024-10-22 | — | — | CN | claimed |
| CN-118767154-A | Multi-arm polyethylene glycol drug conjugate and application thereof | 北京键凯科技股份有限公司 | 2024-10-15 | — | — | CN | claimed |
| CN-118742292-A | Liposome composition and pharmaceutical composition containing liposome | 卫材R&D管理有限公司 | 2024-10-01 | — | — | CN | claimed |
| CN-117947024-A | SiRNA sequence for effectively inhibiting expression of complement C3 factor and application thereof | 北京键凯科技股份有限公司 | 2024-04-30 | — | — | CN | claimed |
| CN-117866955-A | Interference RNA for inhibiting expression of melanin avidin (MLPH) gene and application thereof | 北京键凯科技股份有限公司 | 2024-04-12 | — | — | CN | claimed |
| CN-117487823-A | Respiratory syncytial virus mRNA vaccine and preparation method and application thereof | 怡道生物科技(苏州)有限公司 | 2024-02-02 | — | — | CN | claimed |
| CN-117384055-A | Ionizable lipids for delivery of therapeutic agents and uses thereof | 仁景(苏州)生物科技有限公司 | 2024-01-12 | — | — | CN | claimed |
| CN-117286143-A | Interfering RNA for inhibiting TUBB2 gene expression and application thereof | 北京键凯科技股份有限公司 | 2023-12-26 | — | — | CN | claimed |
| US-10260071-B2 | CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity | COLEY PHARMACEUTICAL GMBH (DE) | 2019-04-16 | — | — | US | claimed |
| US-20160348115-A1 | CpG Oligonucleotide Analogs Containing Hydrophobic T Analogs with Enhanced Immunostimulatory Activity | PFIZER INC. | 2016-12-01 | — | — | US | claimed |
| EP-2078080-B1 | CPG OLIGONUCLEOTIDE ANALOGS CONTAINING HYDROPHOBIC T ANALOGS WITH ENHANCED IMMUNOSTIMULATORY ACTIVITY | COLEY PHARM GMBH (DE) | 2015-06-17 | — | — | EP | claimed |
| US-20140163213-A1 | CpG Oligonucleotide Analogs Containing Hydrophobic T Analogs with Enhanced Immunostimulatory Activity | COLEY PHARMACEUTICAL GMBH (DE) | 2014-06-12 | — | — | US | claimed |
| EP-2057904-B1 | Structured lipid compositions | KRAFT FOODS GLOBAL BRANDS LLC (US) | 2012-04-25 | — | — | EP | claimed |
| WO-2011119058-A2 | F3-PEPTIDE TARGETED LIPID-BASED NANOPARTICLES USEFUL FOR THE TREATMENT OF ANGIOGENESIS-DEPENDENT DISEASES | UNIVERSIDADE DE COIMBRA (PT) | 2011-09-29 | — | — | WO | claimed |
| US-20100166780-A1 | CpG Oligonucleotide Analogs Containing Hydrophobic T Analogs with Enhanced Immunostimulatory Activity | PFIZER INC | 2010-07-01 | — | — | US | claimed |
| EP-2078080-A2 | CPG OLIGONUCLEOTIDE ANALOGS CONTAINING HYDROPHOBIC T ANALOGS WITH ENHANCED IMMUNOSTIMULATORY ACTIVITY | Coley Pharmaceuticals GmbH (DE) | 2009-07-15 | — | — | EP | claimed |
| WO-2008068638-A2 | CPG OLIGONUCLEOTIDE ANALOGS CONTAINING HYDROPHOBIC T ANALOGS WITH ENHANCED IMMUNOSTIMULATORY ACTIVITY | COLEY PHARMACEUTICAL GMBH (DE) | 2008-06-12 | — | — | WO | claimed |
| CN-122079802-A | Cationic lipids and compositions thereof | — | 2026-05-26 | — | — | CN | disclosed |
| US-12569570-B2 | Compositions and methods for targeted RNA delivery | VERVE THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4606388-A9 | METAL-POLYPHENOL COMPLEX PARTICLE, DRUG-LIPID PARTICLE, METHOD FOR PREPARING SAME, AND USE THEREOF | Hunan Lonstar Biotech Co., Ltd. (CN) | 2026-02-25 | — | — | EP | disclosed |
| US-20260048142-A1 | METAL-CHELATED POLYPHENOL COMPLEX NANOPARTICLE, DRUG-LIPID PARTICLE, PREPARATION METHODS FOR THE SAME, AND USES THEREOF | HUNAN LONSTAR BIOTECH CO LTD (CN) | 2026-02-19 | — | — | US | disclosed |
| EP-4678177-A1 | ARENAVIRUS VACCINE | The University of Osaka (JP) | 2026-01-14 | — | — | EP | disclosed |
| EP-4606388-A1 | METAL-POLYPHENOL COMPLEX PARTICLE, DRUG-LIPID PARTICLE, METHOD FOR PREPARING SAME, AND USE THEREOF | Hunan Lonstar Biotech Co., Ltd. (CN) | 2025-08-27 | — | — | EP | disclosed |
| CN-115745788-B | Ionizable lipid compound, and preparation method and application thereof | 国家纳米科学中心 | 2025-06-24 | — | — | CN | disclosed |
| EP-4570271-A1 | METAL-PHOSPHOLIPID COMPLEX, METAL-PHOSPHOLIPID COMPLEX PARTICLE, DRUG-LIPID PARTICLE, METHOD FOR PREPARING SAME, AND USE THEREOF | Hunan Lonstar Biotech Co., Ltd. (CN) | 2025-06-18 | — | — | EP | disclosed |
| CN-120078734-A | Lipid nanoparticle for delivering nucleic acid and preparation method and application thereof | 康希诺(上海)生物研发有限公司 | 2025-06-03 | — | — | CN | disclosed |
| US-12274753-B2 | Compositions and methods for targeted RNA delivery | VERVE THERAPEUTICS, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| CN-119546285-A | Freeze-dried composition of lipid nanoparticles with nucleic acids encapsulated therein | 日油株式会社 | 2025-02-28 | — | — | CN | disclosed |
| CN-119504707-A | Ionizable lipid compounds capable of activating STING signal pathway and application thereof | 四川大学 | 2025-02-25 | — | — | CN | disclosed |
| CN-119345352-A | Engineered cell composition and preparation method and application thereof | 山东汇泽生物制药有限公司 | 2025-01-24 | — | — | CN | disclosed |
| CN-119343153-A | Nucleic acid medicine for treating hyperuricemia related diseases and preparation method and application thereof | 北京炫景瑞医药科技有限公司 | 2025-01-21 | — | — | CN | disclosed |
| CN-119285480-A | Modified amine lipids | 英特利亚治疗股份有限公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-119234042-A | Messenger ribonucleic acid with prolonged half-life | 摩登纳特斯有限公司 | 2024-12-31 | — | — | CN | disclosed |
| CN-119136789-A | Method for producing nucleic acid-encapsulated lipid nanoparticle, method for producing pharmaceutical composition comprising same, and method for introducing nucleic acid into cells or target cells | 日油株式会社 | 2024-12-13 | — | — | CN | disclosed |
| CN-117384055-B | Ionizable lipids for delivery of therapeutic agents and uses thereof | 仁景(苏州)生物科技有限公司 | 2024-11-19 | — | — | CN | disclosed |
| CN-118973618-A | Agents and methods for targeted delivery of nucleic acids to cells | 生物技术欧洲股份公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-118973619-A | Agents and methods for targeted delivery to cells | 生物技术欧洲股份公司 | 2024-11-15 | — | — | CN | disclosed |
| WO-2024222243-A1 | IONIZABLE LIPID FOR DELIVERY OF THERAPEUTIC AGENT AND USE THEREOF | 仁景(苏州)生物科技有限公司 | 2024-10-31 | — | — | WO | disclosed |
| CN-117487823-B | Respiratory syncytial virus mRNA vaccine and preparation method and application thereof | 怡道生物科技(苏州)有限公司 | 2024-10-29 | — | — | CN | disclosed |
| CN-118834136-A | Ionizable lipid compound and application thereof | 上海桢曜生物科技合伙企业(有限合伙) | 2024-10-25 | — | — | CN | disclosed |
| CN-118829625-A | Novel ionizable lipids and lipid nanoparticles and methods of use thereof | 赛欧生物医药股份有限公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-118813629-A | MRNA for expressing aquaporin AQP3 and application thereof | 北京键凯科技股份有限公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-118767154-A | Multi-arm polyethylene glycol drug conjugate and application thereof | 北京键凯科技股份有限公司 | 2024-10-15 | — | — | CN | disclosed |
| CN-118742292-A | Liposome composition and pharmaceutical composition containing liposome | 卫材R&D管理有限公司 | 2024-10-01 | — | — | CN | disclosed |
| US-20240316212-A1 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | VERVE THERAPEUTICS, INC. | 2024-09-26 | — | — | US | disclosed |
| CN-118660960-A | Polynucleotides, compositions and methods for genome editing | 因特利亚治疗公司 | 2024-09-17 | — | — | CN | disclosed |
| CN-118613585-A | Modified guide RNAs for gene editing | 因特利亚治疗公司 | 2024-09-06 | — | — | CN | disclosed |
| CN-118401495-A | Method for purifying composition | JSR株式会社 | 2024-07-26 | — | — | CN | disclosed |
| CN-118384268-A | Methods of treating subjects having Hepatitis B Virus (HBV) infection | 阿尔尼拉姆医药品有限公司 | 2024-07-26 | — | — | CN | disclosed |
| CN-118369111-A | Herpes simplex virus mRNA vaccine | 摩登纳特斯有限公司 | 2024-07-19 | — | — | CN | disclosed |
| CN-118302157-A | Lipid nanoparticles with cell targeting | 日油株式会社 | 2024-07-05 | — | — | CN | disclosed |
| CN-118221556-A | Ionizable cationic lipid material, and preparation method and application thereof | 南京吉迈生物技术有限公司 | 2024-06-21 | — | — | CN | disclosed |
| EP-4380576-A2 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | Verve Therapeutics, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| CN-118125932-A | Application of ionizable lipid molecules and nanoparticle composition thereof in nucleic acid delivery | 北京启辰生生物科技有限公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-118105475-A | Lyophilized preparation of mRNA lipid nanoparticle of 2019-nCoV delta strain S protein mutant | 北京启辰生生物科技有限公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-118078752-A | Lipid composition for gene editing agent delivery and uses thereof | 北京启辰生生物科技有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118103514-A | Cyclic RNA compositions and methods | 欧纳医疗公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-118059222-A | Lyophilized preparation of mRNA lipid nanoparticle of 2019-nCoV S protein | 北京启辰生生物科技有限公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-118059059-A | Freeze-dried preparation of lipid nano particles | 北京启辰生生物科技有限公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-118021754-A | Needleless injector and lipid nanoparticle delivery system | 北京启辰生生物科技有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-117947024-A | SiRNA sequence for effectively inhibiting expression of complement C3 factor and application thereof | 北京键凯科技股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-114728886-B | Lipid compounds and compositions containing carbonates for intracellular delivery of therapeutic agents | 摩登纳特斯有限公司 | 2024-04-12 | — | — | CN | disclosed |
| US-20240100169-A1 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | VERVE THERAPEUTICS, INC. | 2024-03-28 | — | — | US | disclosed |
| CN-117731805-A | Lipid nanoparticle formulations for CRISPR/CAS components | 因特利亚治疗公司 | 2024-03-22 | — | — | CN | disclosed |
| WO-2024032507-A1 | METAL-PHOSPHOLIPID COMPLEX, METAL-PHOSPHOLIPID COMPLEX PARTICLE, DRUG-LIPID PARTICLE, METHOD FOR PREPARING SAME, AND USE THEREOF | 湖南健瑞医药科技有限公司 | 2024-02-15 | — | — | WO | disclosed |
| WO-2024032482-A1 | METAL-POLYPHENOL COMPLEX PARTICLE, DRUG-LIPID PARTICLE, METHOD FOR PREPARING SAME, AND USE THEREOF | 湖南健瑞医药科技有限公司 | 2024-02-15 | — | — | WO | disclosed |
| CN-117534585-A | Novel ionizable cationic lipid compound, and preparation method and application thereof | 国家纳米科学中心 | 2024-02-09 | — | — | CN | disclosed |
| CN-117487823-A | Respiratory syncytial virus mRNA vaccine and preparation method and application thereof | 怡道生物科技(苏州)有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-113699151-B | Hepatitis B Virus (HBV) iRNA compositions and methods of use thereof | 阿尔尼拉姆医药品有限公司 | 2024-01-19 | — | — | CN | disclosed |
| CN-117384055-A | Ionizable lipids for delivery of therapeutic agents and uses thereof | 仁景(苏州)生物科技有限公司 | 2024-01-12 | — | — | CN | disclosed |
| CN-117377653-A | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents | 摩登纳特斯有限公司 | 2024-01-09 | — | — | CN | disclosed |
| CN-117321417-A | Method for determining the efficacy of therapeutic cell compositions | 朱诺治疗学股份有限公司 | 2023-12-29 | — | — | CN | disclosed |
| CN-113039174-B | Ionizable amine lipids | 英特利亚治疗股份有限公司 | 2023-11-17 | — | — | CN | disclosed |
| US-11801306-B2 | Compositions and methods for targeted RNA delivery | VERVE THERAPEUTICS, INC. (US) | 2023-10-31 | — | — | US | disclosed |
| CN-116916896-A | Method for preparing lipid nanoparticles | 摩登纳特斯有限公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-116507344-A | Compositions and methods for inducing an immune response against coronaviruses | 伊莱西奥治疗有限公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-116133652-A | Method for preparing lipid nanoparticles | 摩登纳特斯有限公司 | 2023-05-16 | — | — | CN | disclosed |
| CN-116113419-A | Cyclic RNA compositions and methods | 奥纳治疗公司 | 2023-05-12 | — | — | CN | disclosed |
| CN-116034114-A | Cyclic RNA compositions and methods | 奥纳治疗公司 | 2023-04-28 | — | — | CN | disclosed |
| CN-116018403-A | In vitro cell delivery methods | 因特利亚治疗公司 | 2023-04-25 | — | — | CN | disclosed |
| WO-2023015223-A9 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | VERVE THERAPEUTICS, INC. (US) | 2023-04-06 | — | — | WO | disclosed |
| WO-2023015223-A2 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | VERVE THERAPEUTICS, INC. (US) | 2023-02-09 | — | — | WO | disclosed |
| EP-4114360-A1 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | Verve Therapeutics, Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
| EP-4074344-A1 | TARGETING LIPIDS | Arbutus Biopharma Corporation (CA) | 2022-10-19 | — | — | EP | disclosed |
| CN-114746398-A | Headgroup lipid compounds and compositions for intracellular delivery of therapeutic agents | 摩登纳特斯有限公司 | 2022-07-12 | — | — | CN | disclosed |
| US-20220152210-A1 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | VERVE THERAPEUTICS, INC. | 2022-05-19 | — | — | US | disclosed |
| US-11207416-B2 | Compositions and methods for targeted RNA delivery | VERVE THERAPEUTICS, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-20210299261-A1 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | VERVE THERAPEUTICS, INC. | 2021-09-30 | — | — | US | disclosed |
| WO-2021178725-A1 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | VERVE THERAPEUTICS, INC. (US) | 2021-09-10 | — | — | WO | disclosed |
| US-20210177757-A1 | EXOSOMES FOR DELIVERY OF THERAPEUTIC AGENTS | PURETECH LYT, INC. (US) | 2021-06-17 | — | — | US | disclosed |
| US-10260071-B2 | CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity | COLEY PHARMACEUTICAL GMBH (DE) | 2019-04-16 | — | — | US | disclosed |
| US-20180193270-A1 | EXOSOMES FOR DELIVERY OF THERAPEUTIC AGENTS | PURETECH LYT, INC. | 2018-07-12 | — | — | US | disclosed |
| US-9814777-B2 | Targeting lipids | ARBUTUS BIOPHARMA CORPORATION (CA) | 2017-11-14 | — | — | US | disclosed |
| EP-3156077-A1 | TARGETING LIPIDS | Arbutus Biopharma Corporation (CA) | 2017-04-19 | — | — | EP | disclosed |
| EP-2231195-B1 | TARGETING LIPIDS | ARBUTUS BIOPHARMA CORP (CA) | 2017-03-29 | — | — | EP | disclosed |
| US-20160375137-A9 | TARGETING LIPIDS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2016-12-29 | — | — | US | disclosed |
| US-20160348115-A1 | CpG Oligonucleotide Analogs Containing Hydrophobic T Analogs with Enhanced Immunostimulatory Activity | PFIZER INC. | 2016-12-01 | — | — | US | disclosed |
| US-9453222-B2 | Ligand-conjugated monomers | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-9382545-B2 | CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity | COLEY PHARMACEUTICAL GMBH (DE) | 2016-07-05 | — | — | US | disclosed |
| EP-2990410-A1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES | Alnylam Pharmaceuticals Inc. (US) | 2016-03-02 | — | — | EP | disclosed |
| EP-2960332-A1 | CPG OLIGONUCLEOTIDE ANALOGS CONTAINING HYDROPHOBIC T ANALOGS WITH ENHANCED IMMUNOSTIMULATORY ACTIVITY | Coley Pharmaceutical GmbH (DE) | 2015-12-30 | — | — | EP | disclosed |
| EP-2567693-B1 | Lipid encapsulated interfering RNA | PROTIVA BIOTHERAPEUTICS INC (CA) | 2015-10-21 | — | — | EP | disclosed |
| EP-1791567-B1 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS INC (US) | 2015-07-29 | — | — | EP | disclosed |
| US-20150191726-A1 | LIGAND-CONJUGATED MONOMERS | BANK OF AMERICA, N.A. | 2015-07-09 | — | — | US | disclosed |
| EP-2078080-B1 | CPG OLIGONUCLEOTIDE ANALOGS CONTAINING HYDROPHOBIC T ANALOGS WITH ENHANCED IMMUNOSTIMULATORY ACTIVITY | COLEY PHARM GMBH (DE) | 2015-06-17 | — | — | EP | disclosed |
| US-8957223-B2 | Ligand-conjugated monomers | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-8911813-B2 | Structured lipid compositions | INTERCONTINENTAL GREAT BRANDS LLC (US) | 2014-12-16 | — | — | US | disclosed |
| EP-1648519-B1 | LIPID ENCAPSULATED INTERFERING RNA | PROTIVA BIOTHERAPEUTICS INC (CA) | 2014-10-08 | — | — | EP | disclosed |
| US-20140179761-A1 | TARGETING LIPIDS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2014-06-26 | — | — | US | disclosed |
| US-20140163213-A1 | CpG Oligonucleotide Analogs Containing Hydrophobic T Analogs with Enhanced Immunostimulatory Activity | COLEY PHARMACEUTICAL GMBH (DE) | 2014-06-12 | — | — | US | disclosed |
| US-8580268-B2 | CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity | COLEY PHARMACEUTICAL GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| US-8575380-B2 | Branched polyethylene glycol linked with diacyl glycerol, process for producing the same, and polyethylene glycol modified liposome | NOF CORPORATION (JP) | 2013-11-05 | — | — | US | disclosed |
| US-20130280408-A1 | Structured Lipid Compositions | INTERCONTINENTAL GREAT BRANDS LLC (US) | 2013-10-24 | — | — | US | disclosed |
| US-8507661-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20130184328-A1 | LIGAND-CONJUGATED MONOMERS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-8486478-B2 | Structured lipid compositions | International Great Brands LLC (US) | 2013-07-16 | — | — | US | disclosed |
| US-20130116461-A1 | BRANCHED POLYETHYLENE GLYCOL LINKED WITH DIACYL GLYCEROL, PROCESS FOR PRODUCING THE SAME, AND POLYETHYLENE GLYCOL MODIFIED LIPOSOME | NOF CORPORATION (JP) | 2013-05-09 | — | — | US | disclosed |
| WO-2013054298-A2 | MODIFIED POLYETHYLENE GLYCOLS AND THEIR SUPRAMOLECULAR COMPLEXES WITH BIOLOGICALLY ACTIVE MACROMOLECULES | Bio-Ker S.r.l (IT) | 2013-04-18 | — | — | WO | disclosed |
| US-8404862-B2 | Ligand-conjugated monomers | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-03-26 | — | — | US | disclosed |
| EP-2567693-A1 | Lipid encapsulated interfering RNA | Protiva Biotherapeutics Inc. (CA) | 2013-03-13 | — | — | EP | disclosed |
| EP-2462811-A1 | Structured lipid compositions | Kraft Foods Global Brands LLC (US) | 2012-06-13 | — | — | EP | disclosed |
| EP-2057904-B1 | Structured lipid compositions | KRAFT FOODS GLOBAL BRANDS LLC (US) | 2012-04-25 | — | — | EP | disclosed |
| US-20120058188-A1 | LIPID ENCAPSULATED INTERFERING RNA | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2012-03-08 | — | — | US | disclosed |
| US-20110305770-A1 | RELEASABLE POLYMERIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEM | ENZON PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110269942-A1 | ANTIBODIES MODIFIED WITH HYDROPHOBIC MOLECULE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-11-03 | — | — | US | disclosed |
| WO-2011119058-A2 | F3-PEPTIDE TARGETED LIPID-BASED NANOPARTICLES USEFUL FOR THE TREATMENT OF ANGIOGENESIS-DEPENDENT DISEASES | UNIVERSIDADE DE COIMBRA (PT) | 2011-09-29 | — | — | WO | disclosed |
| US-20110223257-A1 | RELEASABLE FUSOGENIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEMS | ENZON PHARMACEUTICALS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| EP-2362728-A1 | RELEASABLE POLYMERIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEM | Enzon Pharmaceuticals, Inc. (US) | 2011-09-07 | — | — | EP | disclosed |
| EP-2355799-A1 | RELEASABLE FUSOGENIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEMS | Enzon Pharmaceuticals, Inc. (US) | 2011-08-17 | — | — | EP | disclosed |
| US-7982027-B2 | silencing gene expression by delivering nucleic acid-lipid particles comprising a siRNA molecule to a cell; hepatitis | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2011-07-19 | — | — | US | disclosed |
| WO-2010057160-A9 | RELEASABLE FUSOGENIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEMS | ENZON PHARMACEUTICALS, INC. (US) | 2011-05-05 | — | — | WO | disclosed |
| US-20100292455-A1 | MODIFIED iRNA AGENTS | ALNYLAM PHARMACEUTICALS (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100279990-A1 | ANTIPROLIFERATIVE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2010-11-04 | — | — | US | disclosed |
| US-7807815-B2 | Compositions comprising immunostimulatory siRNA molecules and DLinDMA or DLenDMA | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2010-10-05 | — | — | US | disclosed |
| EP-2231195-A2 | TARGETING LIPIDS | Alnylam Pharmaceuticals Inc. (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20100166780-A1 | CpG Oligonucleotide Analogs Containing Hydrophobic T Analogs with Enhanced Immunostimulatory Activity | PFIZER INC | 2010-07-01 | — | — | US | disclosed |
| US-7745608-B2 | Modified iRNA agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-20100130549-A1 | PSYCHOTROPIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2010-05-27 | — | — | US | disclosed |
| WO-2010057150-A1 | RELEASABLE POLYMERIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEMS | ENZON PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010057160-A1 | RELEASABLE FUSOGENIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEMS | ENZON PHARMACEUTICALS, INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| EP-2184355-A1 | ANTIBODY MODIFIED WITH HYDROPHOBIC MOLECULE | Daiichi Sankyo Company, Limited (JP) | 2010-05-12 | — | — | EP | disclosed |
| EP-2120907-A1 | PSYCHOTROPIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Ramot at Tel-Aviv University Ltd (IL) | 2009-11-25 | — | — | EP | disclosed |
| US-20090286973-A1 | LIGAND-CONJUGATED MONOMERS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090247608-A1 | Targeting Lipids | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-7582744-B2 | containing 2'-O-methyl modified nucleoside; oligonucleotide having a nucleotide sequence consisting of from 12 to 23 nucleotides in length sufficiently complementary to a microRNA target sequence of about 12 to 23 nucleotides, conjugate with a cholesterol or steroid; for inhibiting gene expression | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| EP-2078080-A2 | CPG OLIGONUCLEOTIDE ANALOGS CONTAINING HYDROPHOBIC T ANALOGS WITH ENHANCED IMMUNOSTIMULATORY ACTIVITY | Coley Pharmaceuticals GmbH (DE) | 2009-07-15 | — | — | EP | disclosed |
| WO-2009082607-A2 | TARGETING LIPIDS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-07-02 | — | — | WO | disclosed |
| US-20090142362-A1 | Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP) | AVANT IMMUNOTHERAPEUTICS, INC. (US) | 2009-06-04 | — | — | US | disclosed |
| US-20090123635-A1 | Structured Lipid Compositions | INTERCONTINENTAL GREAT BRANDS LLC | 2009-05-14 | — | — | US | disclosed |
| EP-2057904-A1 | Structured lipid compositions | Kraft Foods Global Brands LLC (US) | 2009-05-13 | — | — | EP | disclosed |
| EP-2029517-A2 | ANTIPROLIFERATIVE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Ramot at Tel-Aviv University Ltd. (IL) | 2009-03-04 | — | — | EP | disclosed |
| WO-2008057529-A9 | PEPTIDE-BASED VACCINE COMPOSITIONS TO ENDOGENOUS CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) | COLEY PHARM GROUP INC (US) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008084484-A1 | PSYCHOTROPIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE | RAMOT AT TEL-AVIV UNIVERSITY LTD (IL) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008068638-A2 | CPG OLIGONUCLEOTIDE ANALOGS CONTAINING HYDROPHOBIC T ANALOGS WITH ENHANCED IMMUNOSTIMULATORY ACTIVITY | COLEY PHARMACEUTICAL GMBH (DE) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008057529-A2 | PEPTIDE-BASED VACCINE COMPOSITIONS TO ENDOGENOUS CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2007146796-A2 | ANTIPROLIFERATIVE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2007-12-21 | — | — | WO | disclosed |
| EP-1791567-A2 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES | Alnylam Pharmaceuticals Inc. (US) | 2007-06-06 | — | — | EP | disclosed |
| EP-1773857-A1 | IMMUNOSTIMULATORY SIRNA MOLECULES AND USES THEREFOR | Protiva Biotherapeutics Inc. (CA) | 2007-04-18 | — | — | EP | disclosed |
| US-20060240093-A1 | LIPID ENCAPSULATED INTERFERING RNA | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2006-10-26 | — | — | US | disclosed |
| EP-1648519-A2 | LIPID ENCAPSULATED INTERFERING RNA | Protiva Biotherapeutics Inc. (CA) | 2006-04-26 | — | — | EP | disclosed |
| US-20060058266-A1 | containing 2'-O-methyl modified nucleoside; oligonucleotide having a nucleotide sequence consisting of from 12 to 23 nucleotides in length sufficiently complementary to a microRNA target sequence of about 12 to 23 nucleotides, conjugate with a cholesterol or steroid; for inhibiting gene expression | BANK OF AMERICA, N.A. | 2006-03-16 | — | — | US | disclosed |
| US-20060051405-A1 | Compositions for the delivery of therapeutic agents and uses thereof | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2006-03-09 | — | — | US | disclosed |
| WO-2006020768-A2 | CHEMICALLY MODIFIED OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| US-20060025366-A1 | Immunostimulatory siRNA molecules and uses therefor | PROTIVA BIOTHERAPEUTICS, INC. (GB) | 2006-02-02 | — | — | US | disclosed |
| WO-2006007712-A1 | METHODS COMPRISING POLYETHYLENE GLYCOL-LIPID CONJUGATES FOR DELIVERY OF THERAPEUTIC AGENTS | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2006-01-26 | — | — | WO | disclosed |
| WO-2006002538-A1 | IMMUNOSTIMULATORY SIRNA MOLECULES AND USES THEREFOR | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2006-01-12 | — | — | WO | disclosed |
| US-20050107325-A1 | Conjugated lipophilic group with a modified nucleotide is used to target disease gene, cells, tissue, for drug delivery to entrance into tumor cells; ribose sugar of nucleotide is replaced with a cyclic carrier which has at least one attached phosphate or phosphorothioate group; antitumor biodrugs | ALNYLAM PHARMACEUTICALS, INC. | 2005-05-19 | — | — | US | disclosed |
| US-20050064595-A1 | Lipid encapsulated interfering RNA | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2005-03-24 | — | — | US | disclosed |
| WO-2005007196-A2 | LIPID ENCAPSULATED INTERFERING RNA | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2005-01-27 | — | — | WO | disclosed |
| WO-2002102169-A2 | SYNTHETIC FAT COMPOSITION | THIXO LTD. (IL) | 2002-12-27 | — | — | WO | disclosed |
| US-20020132035-A1 | Synthetic fat composition | TAMARKIN DOV (IL) | 2002-09-19 | — | — | US | disclosed |
| EP-0571724-B1 | Stabilizer for phospholipid vesicles | CHIBA FLOUR MILLING (JP) | 1997-06-04 | — | — | EP | disclosed |
| US-5472951-A | Containing lipopolysaccharide having hydrophobic group linked through an amide linkage to a stereoisomeric carbon at a reducing end group of an aldose | CHIBA FLOUR MILLING CO., LTD. (JP) | 1995-12-05 | — | — | US | disclosed |
| EP-0571724-A1 | Stabilizer for phospholipid vesicles | CHIBA FLOUR MILLING CO. LTD. (JP) | 1993-12-01 | — | — | EP | disclosed |
| EP-0321548-A4 | NOVEL AMPHIPHILIC NUCLEIC ACID CONJUGATES | — | 1991-01-30 | — | — | EP | disclosed |
| US-4904582-A | Novel amphiphilic nucleic acid conjugates | SYNTHETIC GENETICS (US) | 1990-02-27 | — | — | US | disclosed |
| EP-0321548-A1 | NOVEL AMPHIPHILIC NUCLEIC ACID CONJUGATES | SYNTHETIC GENETICS (US) | 1989-06-28 | — | — | EP | disclosed |
| WO-1988009810-A1 | NOVEL AMPHIPHILIC NUCLEIC ACID CONJUGATES | SYNTHETIC GENETICS (US) | 1988-12-15 | — | — | WO | disclosed |
| WO-1988009810-A1 | NOVEL AMPHIPHILIC NUCLEIC ACID CONJUGATES | SYNTHETIC GENETICS (US) | 1988-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (32 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12274753-B2 | Compositions and methods for targeted RNA delivery | PCSK9, LDLR, PCSK7 | LMNA 127/4885FDPS 3130/4885GGPS1 1855/4885 |
| US-20180193270-A1 | EXOSOMES FOR DELIVERY OF THERAPEUTIC AGENTS | EXOSC5, EXOSC9, EXOSC10 | LMNA 3167/4885FDPS 4415/4885GGPS1 3264/4885 |
| US-20090247608-A1 | Targeting Lipids | LY96, ABHD10, APOB | LMNA 180/4885FDPS 1893/4885GGPS1 872/4885 |
| US-20100279990-A1 | ANTIPROLIFERATIVE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | STRA6, GPR6, CCNO | LMNA 3449/4885FDPS 3786/4885GGPS1 3031/4885 |
| US-20060058266-A1 | containing 2'-O-methyl modified nucleoside; oligonucleotide having a nucleotide sequence consisting of from 12 to 23 nucleotides in length sufficiently complementary to a microRNA target sequence of about 12 to 23 nucleotides, conjugate with a cholesterol or steroid; for inhibiting gene expression | NSUN2, RNMT, RNGTT | LMNA 2496/4885FDPS 1386/4885GGPS1 471/4885 |
| US-20240100169-A1 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | PCSK9, LDLR, PCSK7 | LMNA 127/4885FDPS 3130/4885GGPS1 1855/4885 |
| US-20110305770-A1 | RELEASABLE POLYMERIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEM | KPNA6, LPAR6, KAT6B | LMNA 276/4885FDPS 3395/4885GGPS1 1683/4885 |
| US-20130184328-A1 | LIGAND-CONJUGATED MONOMERS | TNFSF11, BCDIN3D, CD40LG | LMNA 3599/4885FDPS 2341/4885GGPS1 1659/4885 |
| US-20210177757-A1 | EXOSOMES FOR DELIVERY OF THERAPEUTIC AGENTS | EXOSC5, EXOSC9, EXOSC10 | LMNA 3167/4885FDPS 4415/4885GGPS1 3264/4885 |
| US-20110223257-A1 | RELEASABLE FUSOGENIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEMS | FUS, HNRNPUL2, HNRNPDL | LMNA 530/4885FDPS 1064/4885GGPS1 1100/4885 |
| US-20100292455-A1 | MODIFIED iRNA AGENTS | NCL, HNRNPA0, HNRNPA1 | LMNA 56/4885FDPS 1225/4885GGPS1 811/4885 |
| US-20050064595-A1 | Lipid encapsulated interfering RNA | ABHD16A, LDLR, RNASE1 | LMNA 1007/4885FDPS 2172/4885GGPS1 619/4885 |
| US-20150191726-A1 | LIGAND-CONJUGATED MONOMERS | TNFSF11, BCDIN3D, CD40LG | LMNA 3599/4885FDPS 2341/4885GGPS1 1659/4885 |
| US-20120058188-A1 | LIPID ENCAPSULATED INTERFERING RNA | ABHD16A, LDLR, RNASE1 | LMNA 1007/4885FDPS 2172/4885GGPS1 619/4885 |
| US-20140179761-A1 | TARGETING LIPIDS | LY96, ABHD10, APOB | LMNA 169/4885FDPS 1928/4885GGPS1 879/4885 |
| US-12569570-B2 | Compositions and methods for targeted RNA delivery | LDLR, ASGR1, PCSK9 | LMNA 63/4885FDPS 4013/4885GGPS1 1626/4885 |
| US-20100130549-A1 | PSYCHOTROPIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE | SLC6A2, CHRNA6, SLC6A3 | LMNA 3494/4885FDPS 4655/4885GGPS1 4038/4885 |
| US-20060240093-A1 | LIPID ENCAPSULATED INTERFERING RNA | ABHD16A, LDLR, RNASE1 | LMNA 1007/4885FDPS 2172/4885GGPS1 619/4885 |
| US-20100166780-A1 | CpG Oligonucleotide Analogs Containing Hydrophobic T Analogs with Enhanced Immunostimulatory Activity | TLR9, TYMP, STING1 | LMNA 4419/4885FDPS 1275/4885GGPS1 528/4885 |
| US-10260071-B2 | CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity | TLR9, TYMP, STING1 | LMNA 4419/4885FDPS 1275/4885GGPS1 528/4885 |
| US-20240316212-A1 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | PCSK9, LDLR, PCSK7 | LMNA 135/4885FDPS 2396/4885GGPS1 2053/4885 |
| US-20060051405-A1 | Compositions for the delivery of therapeutic agents and uses thereof | PNLIP, SGPL1, PLTP | LMNA 1788/4885FDPS 448/4885GGPS1 168/4885 |
| US-20220152210-A1 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | PCSK9, LDLR, PCSK7 | LMNA 127/4885FDPS 3130/4885GGPS1 1855/4885 |
| US-20090142362-A1 | Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP) | CETP, PCTP, LCAT | LMNA 2968/4885FDPS 420/4885GGPS1 277/4885 |
| US-11207416-B2 | Compositions and methods for targeted RNA delivery | PCSK9, LDLR, PCSK7 | LMNA 127/4885FDPS 3130/4885GGPS1 1855/4885 |
| US-20260048142-A1 | METAL-CHELATED POLYPHENOL COMPLEX NANOPARTICLE, DRUG-LIPID PARTICLE, PREPARATION METHODS FOR THE SAME, AND USES THEREOF | HAMP, ELP1, LIPC | LMNA 1077/4885FDPS 1591/4885GGPS1 2673/4885 |
| US-20050107325-A1 | Conjugated lipophilic group with a modified nucleotide is used to target disease gene, cells, tissue, for drug delivery to entrance into tumor cells; ribose sugar of nucleotide is replaced with a cyclic carrier which has at least one attached phosphate or phosphorothioate group; antitumor biodrugs | LDLR, SLC29A1, SLC29A2 | LMNA 295/4885FDPS 1287/4885GGPS1 594/4885 |
| US-20210299261-A1 | COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERY | PCSK9, LDLR, PCSK7 | LMNA 127/4885FDPS 3130/4885GGPS1 1855/4885 |
| US-20090286973-A1 | LIGAND-CONJUGATED MONOMERS | TNFSF11, BCDIN3D, CD40LG | LMNA 3599/4885FDPS 2341/4885GGPS1 1659/4885 |
| US-11801306-B2 | Compositions and methods for targeted RNA delivery | PCSK9, LDLR, PCSK7 | LMNA 127/4885FDPS 3130/4885GGPS1 1855/4885 |
| US-20060025366-A1 | Immunostimulatory siRNA molecules and uses therefor | HAVCR2, CD74, STING1 | LMNA 4187/4885FDPS 2135/4885GGPS1 673/4885 |
| US-20160375137-A9 | TARGETING LIPIDS | LY96, ABHD10, APOB | LMNA 169/4885FDPS 1928/4885GGPS1 879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.